US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Target starts price war with Walmart by slashing the cost of 5,000 popular items
Target will be lowering prices on at least 5,000 frequently bought products ranging from milk to dia2024-05-21- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
Court, Federation Publicize Top Cases Involving Protection of Minors' Rights
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Federation Strengthens Girls' Legal Protection
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21FDIC chairman Martin Gruenberg to step down, White House says
NEW YORK (AP) — The White House said Monday that the chairman of the Federal Deposit Insurance Corpo2024-05-21Media Briefing Showcases Achievements in Protection of Mudanjiang Women's Rights
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment